Western Standard LLC’s ANI Pharmaceuticals ANIP Stock Holding History

Western Standard LLC’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,800	Closed	-$693K	–	44
2017 Q2	$693K	Buy	+14,800	New	+$714K	0.95%	23

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Western Standard LLC's ANIP Position: Q3 2017 in Review

Western Standard LLC sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 14,800 shares — an estimated $693K sold.

Western Standard LLC first reported a position in ANIP in Q2 2017 and held it in 1 quarter. The position peaked at $693K in Q2 2017. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

Western Standard LLC reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Western Standard LLC sold 14,800 ANI Pharmaceuticals shares in Q3 2017, an estimated $693K.
Western Standard LLC first reported a position in ANI Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Western Standard LLC's ANI Pharmaceuticals position peaked at $693K in Q2 2017.
146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Western Standard LLC's 13F filing for Q3 2017, filed 14 Nov 2017.